Trial Profile
A Phase 1b Study of Bavituximab Plus Carboplatin and Pemetrexed in Chemotherapy-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 12 Jun 2017 Status changed from active, no longer recruiting to completed.
- 09 May 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
- 29 Dec 2014 Planned End Date changed from 1 May 2018 to 1 May 2016 as reported by ClinicalTrials.gov record.